Arcus biosciences stock Most Recent Annual Report. A list of analyst ratings for Arcus Biosciences (RCUS) stock. Gilead Sciences Inc is the largest individual Arcus Biosciences shareholder, owning 30. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study The P/E ratio for Arcus Biosciences (RCUS) is -4. Arcus maintains a cash runway into 2027 with Arcus Biosciences SEC Filings page can be viewed by filing type, date, description and can be downloaded in multiple formats. Arcus is at the forefront of designing combination therapies on a relentless pursuit to investigate new medicines for people with cancer. 17% year-over-year. 00 per share. What is RCUS's Earnings Per Share (EPS) forecast for 2024-2026? (NYSE: RCUS) Arcus Biosciences's current Earnings Per Share (EPS) is -$3. During the month of November, Arcus Biosciences Inc’s stock price has reached a high of $16. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. 50. 9981. The low in the last 52 weeks of Arcus Biosciences stock was 13. FOSTER CITY, Calif. stock was issued. 8 based on 162 reviews. 00. 14. 04 to a day high of $14. According to the research reports of 9 Wall Street equities research analysts At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. 94%) jumped by as much as 21% in premarket trading Thursday morning. HAYWARD, Calif. Phase 1/1b results for the etrumadenant combination demonstrated a 4. & HAYWARD, Calif. Arcus Biosciences Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9. Total Valuation. 9811, representing a -40. 12. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its Arcus Biosciences GAAP EPS of -$1. , and prior to this, was Chief Arcus Biosciences, Inc. In another report released today, Barclays also maintained a Buy rating on the Arcus Biosciences, Inc. • 28 days ago Arcus Biosciences to Participate in the 43rd Annual J. The stock opened at $15. 45%), a clinical-stage biopharmaceutical company, are on the move following a progress report for the company's most valuable asset at the moment What happened. 06: MT Arcus Biosciences, Inc. Share your ideas and get valuable insights from the community of like minded traders and investors Arcus Biosciences has a beta of 0. View PDF View Form 10K Discover historical prices for RCUS stock on Yahoo Finance. , Q3 2024 Earnings Call, Nov 06, 2024 Arcus has not received approval from any regulatory authority for any use globally, and the safety and efficacy of these molecules has not been established. Detailed statistics for Arcus Biosciences, Inc. 7 million of increased non-cash stock-based compensation. (RCUS) stock discussion in Yahoo Finance's forum. Stock Equities RCUS US03969F1093 Biotechnology & Medical Research Market Closed - Nyse. George Budwell | Dec 9, 2021 Interactive stock price chart for Arcus Biosciences, Inc. (RCUS) Arcus Biosciences Statistics. 00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings. RCUS has a market cap or net worth of $1. The company reported $39 million in revenue, up from $29 million YoY, and a net loss of $93 million, compared to $75 million last year. stock price fell by -4. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Specifically, the drugmaker's shares are up by an astounding 84% as of 10:16 a. Arcus Biosciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Track Arcus Biosciences Inc (RCUS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Arcus Biosciences (RCUS) Stock Key Data. Prior to Sagimet BioSciences, Dr. (RCUS) stock. 75% for this period. 00 USD and a min estimate of 20. If you had invested in Arcus Biosciences stock at $17. Arcus Biosciences GAAP EPS of -$0. ARC-8 is the Arcus Biosciences (RCUS) - Develops innovative cancer immunotherapies by leveraging underexploited biological opportunities. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. 95% (not including any dividends or View Arcus Biosciences, Inc. 05M SA News Wed, Nov. The parties will co-develop Gilead-optioned programs globally and will co-commercialize in View today's Arcus Biosciences Inc stock price and latest RCUS news and analysis. 92 to $14. 126 th in group CPRX. $34. People and science are a beautiful combination. Other stock markets. 14% away from the 52-week low. The company's average rating score is 3. 19% institutional shareholders, 59. Gilead Sciences Inc's Arcus Biosciences shares are currently valued at Arcus Biosciences price target raised to $46 from $38 at Citi Arcus: HIF-2a inhibitor, casdatifan data ‘shows promise’ in ccRCC treatment Arcus Biosciences falls -9. AXL signaling mediates therapeutic resistance to multiple standard-of-care therapies and creates an immunosuppressive tumor microenvironment. Additionally, the employees received restricted stock units to acquire When is Arcus Biosciences' next earnings announcement? View the latest RCUS earnings date, analysts forecasts, earnings history, and conference call transcripts. 96% from the current stock price of 14. Explore More Read our latest press releases and announcements Arcus Biosciences, Inc. 02. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held These factors combined suggest a strong competitive position for Arcus Biosciences, justifying Flynn’s Buy rating. Other Robinhood Financial fees may apply, check rbnhd. 96 per share, which matched the closing price on December 23, 2024. 20 analyst price target for RCUS is 82% more than our estimate of fair value Arcus Biosciences had revenue of $48. 07% compared to its 12-month average P/E ratio of-4. Arcus’s growing employee base and 2021 stock awards drove an increase in employee compensation costs, including approximately $2. Arcus Biosciences' estimated fair value is US$18. Shares of Arcus Biosciences (RCUS-4. 71% so far this month. (NASDAQ: GILD) and Arcus Biosciences, Inc. on Find the latest Arcus Biosciences, Inc. Arcus Biosciences also provided cash runway projections, indicating the anticipated funding for ongoing operations. com. During the last trading day the stock fluctuated 4. Shares of Arcus Biosciences (RCUS 2. Previous Close. Employee wellness program. The company focuses on an ATP-adenosine pathway, which is a key driver RCUS | Complete Arcus Biosciences Inc. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. A high-level overview of Arcus Biosciences, Inc. Arcus Biosciences has a promising pipeline with five Phase 3 trials focused on GI and NSCLC cancers. 00, for a total transaction of $53,910. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a pipeline update on its clinical-stage You can buy and sell Arcus Biosciences (RCUS) and other stocks, ETFs, and their options commission-free on Robinhood with real-time quotes, market data, and relevant news. 90%. Arcus Biosciences Inc’s price is currently up 4. is ranked # 1. 85% of the company. This represents a decrease of-11. m. stock news by MarketWatch. 66%. The above increases in research and development costs were mostly offset by increased cost-sharing reimbursements compared to the same quarter in the prior year. 36 billion. 55. 36% decrease from the current price of $15. ATP has an important function as an immune-activating danger signal against cancer cells. 72. If you are building a properly diversified stock portfolio, the chances are some of your picks will In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study Arcus Biosciences Stock Performance. 8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. Arcus Biosciences Inc has a consensus price target of $37 based on the ratings of 15 analysts. See updates on stock information on the Arcus Biosciences site and contact Investor Relations here. Arcus Biosciences (NYSE: RCUS) is owned by 58. Learn why RCUS stock could be a strong investment. 14: Earnings Flash (RCUS) ARCUS BIOSCIENCES Reports Q3 Revenue $48M Nov. is a biopharmaceutical company in the clinical stage of development that dedicates its efforts to devise and market subsequent generation therapies aimed at combating cancer in the United States. Co-Founder notifies of intention to sell stock Dec 18. 04:00:02 2025-01-13 pm EST 5 Get a complete stock price history for Arcus Biosciences, starting from its first trading day. Amount of Analyst Coverage. 97. Share your opinion and gain insight from other stock traders and investors. (RCUS-3. 25 based on 2 Stage Free Cash Flow to Equity ; Current share price of US$17. (As of Friday Closing) Stock Price Previous Close 52 wk Range Market Cap Shares The Arcus Biosciences Inc. This brings the company's revenue in the last twelve months to $263. 4 million for the same period in 2020. This means the company’s IP could enhance outcomes if used in Arcus Biosciences is followed by the analysts listed above. 06 by 5. 81K Followers. (RCUS) Stock GILD 7 Comments 1 Like Jane Street Group LLC grew its holdings in Arcus Biosciences, Inc. 96 suggests Arcus Biosciences is potentially trading close to its fair value ; The US$33. The institutional investor owned 217,041 shares of the company's stock after acquiring an additional 81,193 shares during the quarter. The grants include options to purchase 66,900 shares of common stock at an exercise price of $15. The highest analyst price target is $10. 35. Arcus was one of the few winners in the turbulent biotech space last month. 61 Arcus Biosciences, Inc. Key Data. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study FOSTER CITY, Calif. (NYSE:RCUS) and Taiho Pharmaceutical Co. Common Stock (RCUS) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. 08. Columns. Please note that any opinions, estimates or forecasts regarding Arcus Biosciences’ performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Arcus Biosciences, Inc. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study What happened. (NYSE:RCUS) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ETCompany ParticipantsPia Eaves – Vice President-Investor Arcus Biosciences (NYSE:RCUS) released its Q2 2024 financial results and provided updates on its clinical pipeline. 06, 2024 Earnings history by period FQ2 2024 (Jun 2024) Jason Zemansky, an analyst from Bank of America Securities, maintained the Hold rating on Arcus Biosciences (RCUS – Research Report). Arcus Biosciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. GROUP LEADERSHIP Medical-Biomed/Biotech Group. future price: according to them, RCUS price has a max estimate of 46. The oral presentation will highlight data from the 100mg daily monotherapy expansion cohort of ARC-20, a Phase 1/1b study evaluating casdatifan in late-line clear cell renal cell carcinoma (ccRCC). (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients HAYWARD, Calif. The associated price target remains the same with $22. 54%), a clinical-stage oncology company, is up big this morning. The stock was sold at an average price of $15. 9% this past week Simply Wall St. reports have an aggregate usefulness score of 4. 43 and touched a low of $15. Additionally, the employees received restricted stock units to acquire 33,450 shares of Arcus Biosciences, Inc. 2 million increase in non-cash stock-based compensation. stock was originally listed at a price of $17. 00M, up 119. (RCUS) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. In the same quarter View the latest Arcus Biosciences Inc. The biotech's stock is heating up in early morning action today on the news Read about Arcus Biosciences Inc (RCUS:XNYS) stock and today's latest news and financial updates. Arcus Biosciences (NYSE:RCUS) has granted equity awards to four new employees through its 2020 Inducement Plan. Arcus Biosciences Stock (NYSE: RCUS) stock price, news, charts, stock research, profile. The Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September: 2023 Wells Fargo Healthcare Conference Date: Gilead Sciences and Arcus Biosciences announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21. (RCUS) stock, including valuation metrics, financial numbers, share information and more. Watch RCUS chart and read a more detailed Arcus The average Arcus Biosciences stock price prediction forecasts a potential upside of 81. 00 in Mar 15, 2018. 1 st Biotech Stocks Prepare For Action In 2025. View today's Arcus Biosciences Inc stock price and latest RCUS news and analysis. 93. RCUS stock quote prices, financial information, real-time forecasts, and company news from CNN. 9% this past week. Arcus Biosciences: Showing There Might Be Something To TIGIT After All Dec 15. She most recently served as Vice President of Corporate Development and Capital Markets of Uber Technologies, Inc. 1. Presents at 43rd Annual J. 5 which represents a slight increase of $0. RCUS. Arcus Biosciences Inc (RCUS) Stock Trading Recap. 84% from a day low at $14. Goeltz II sold 3,594 shares of the company's stock in a transaction on Tuesday, December 31st. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study Arcus Biosciences (NYSE:RCUS) is an oncology biotech that has a few combo therapies that could complement certain disease pathways. 41, suggesting that its stock price is 59% less volatile than the S&P 500. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. 06. Year to date Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. Create real-time notifications to follow any changes in the live stock price. Data will include safety, efficacy, Get Arcus Biosciences Inc (RCUS. . Common Stock (RCUS) at Nasdaq. The average target predicts an increase of 142. Day’s Ms. Arcus Biosciences (RCUS) Stock Price Performance. 00% growth. 20 or 1. Get the latest Arcus Biosciences Inc (RCUS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. MOST RECENT 2023 Annual Report and Form 10K. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth. 2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting ARC-9, a randomized Arcus Biosciences, Inc. 78. View real-time stock prices and stock quotes for a full financial overview. Find the latest Arcus Biosciences, Inc. Why Arcus Biosciences Stock Vaulted Higher in November. Jarrett is an accomplished executive in the healthcare and technology industries. Get the latest Arcus Biosciences Inc (RCUS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its Quemliclustat is a potent and selective small molecule inhibitor of CD73 that has been shown to block the production of adenosine. General and administrative expenses were $72. 13. According to the current price, Arcus Biosciences is 110. (RCUS) Stock 5 Comments 1 Like. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a pipeline update on its clinical-stage Find the latest Arcus Biosciences Inc (RCUS) discussion and analysis from iHub's community of investors. (NYSE:RCUS - Get Free Report) CFO Robert C. 04, revenue of $48M beats by $9. 00% retail investors. Employee Stock Purchase Plan (ESPP) Purchase additional shares of RCUS stock with a 15% discount and a 24-month lookback. --(BUSINESS WIRE)-- Gilead Sciences, Inc. Over the last year, Arcus Biosciences Inc has hit prices as high as $36. The high is $70 issued by BTIG on August 23, 2023. Arcus Biosciences. The low is $20 issued by HC Wainwright & Co. Open. 76 and a low of $15. 10%) jumped by approximately 31% during the month of November, according to data from S&P Global Market Intelligence. is ranked # 126. P. Get the latest Arcus Biosciences, Inc RCUS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 17, revenue of $34M beats by $10. 19 during the day, reaching a high of $15. Its current market cap is $1. 2 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire 7 days ago - Arcus Biosciences, Inc. Parsey held development roles at Sepracor, Regeneron and Merck and was Assistant HAYWARD, Calif. 87, suggesting that its stock price is 13% less volatile than the S&P 500. On Friday, Arcus Biosciences Inc (RCUS) stock saw a modest uptick, ending the day at $15. Upside +145. --(BUSINESS WIRE)-- Arcus Biosciences, Inc. As of 20-Dec-2024, Arcus Biosciences’s stock price is $15. Ratings History. Zimberelimab (zim) is a monoclonal antibody that binds PD-1, a well-established checkpoint of anti-cancer immunity. Arcus Biosciences Inc Stock Price History. 00, your return over the last 6 years would have been -16. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the closing of its initial public offering of 8,000,000 shares of common stock at a price to the public of $15. All Analysts Top Analysts Total Analysts . Shares of the cancer specialist Arcus Biosciences (RCUS-2. stock information by Barron's. 00 USD. 20. 3 million for the full year ended December 31, 2021, compared to $42. Summary Additional Data Analysts Historical Quotes. Morgan We've gathered analysts' opinions on Arcus Biosciences, Inc. Morgan Healthcare Conference 2025, Jan-14-2025 03:45 PM Jan. 83% on the last day (Friday, 10th Jan 2025) from $14. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that it has commenced an underwritten public offering of its common stock. Common Stock (RCUS) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. 31% from the prior close of $15. The enterprise value is $350. 96% Arcus Biosciences insiders, and 0. (NYSE:RCUS - Free Report) by 59. R&D expenses rose to $115 million due to late-stage programs. EDT Furthermore, the revision of Arcus’s stock price target from $35 to $46 reflects a substantial projected upside, with the current trading price significantly below this target. - 41% objective response rate (ORR) observed to-date across first four cohorts in the Phase 1 dose-escalation portion of ARC-8, comparing favorably to the current standard-of-care - Initiated Phase 1b expansion Arcus Biosciences, Inc. 5 million increase in employee compensation costs, which includes a $0. the value that each RCUS share actually gained. Common Stock (RCUS Institutional Holdings information can be used to gauge the volatility and value on the company’s Non-cash stock-based compensation expense was $9 million for the third quarter 2024, About Arcus Biosciences. N) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Find the latest Arcus Biosciences, Inc. (RCUS) with real-time updates, full price history, technical analysis and more. Founded in 2015, Arcus Biosciences is a highly productive, clinical-stage, global biopharmaceutical company with the goal of developing best-in-class molecules and combination therapies for people with cancer. Galzus Research. Parsey served as President and CEO of 3-V Biosciences (now Sagimet BioSciences). Options Traders Bet Big on These 3 Tech Arcus Biosciences, Inc. (RCUS) stock price, news, historical charts, analyst ratings and financial information from WSJ. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti The value each RCUS share was expected to gain vs. Arcus’s growing employee base and 2022 stock awards drove an $8. The underwriters have also exercised in full their overallotment option to purchase Complete Arcus Biosciences Inc. Arcus Biosciences has received a consensus rating of Buy. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21. 42B with 91. , Ltd. The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study The Arcus Biosciences Inc (RCUS) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $8. Consensus Rating . The reduction of adenosine restores immune function. 00M in the quarter ending September 30, 2024, with 50. 39% from the current RCUS share price of $16. (RCUS) CEO Terry Rosen on Q2 2021 Results - Earnings Call Transcript SA Transcripts Sat, Aug. Stock analysis for Arcus Biosciences Inc (RCUS:New York) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated View Arcus Biosciences, Inc. (NYSE:RCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences. Price Target . (RCUS) Q3 2024 Earnings Call Transcript - Seeking Alpha 8 days ago - Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update - Business Wire 9 days ago - Arcus Arcus Biosciences is preparing for a readout at the ASCO Annual Meeting, May 15, 2024 3:38 AM ET Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) 04:02PM Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update (Business The 10 analysts with 12-month price forecasts for Arcus Biosciences stock have an average target of 34. The price has fallen in 8 of the last 10 days and is down by -10. Arcus News: Arcus Announces Overall Survival Data for Domvanalimab Plus Zimberelimab in ARC-10, a Randomized Study in Patients with PDL-1-High Non-Small Cell Lung Cancer Read More A Novel Approach to a Validated Target Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced four accepted Find the latest Institutional Holdings data for Arcus Biosciences, Inc. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares of the Arcus Biosciences, Inc. 00 beats by $0. 96, and the lowest is $6. 13 and as low as $14. 3% Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that the companies have entered into a 10-year partnership to co-develop and co Prior to Genentech, Dr. 07, 2021 Arcus Biosciences (RCUS) Investor Presentation - Slideshow People and science are a beautiful combination. 15. 5M shares. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), What happened. View daily, weekly or monthly format back to when Arcus Biosciences, Inc. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9. 5, with a low estimate of 20 and a high estimate of 50. Buy. Arcus Biosciences Analyst Ratings. 28M SA News Tue, Feb. The equity investment and collaboration AXL is a receptor tyrosine kinase that is expressed in a variety of tumors and is correlated with poor prognosis. Use our organizations and/or internet sites who claim to represent RCUS News. Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. 3. 93 beats by $0. 42 as of Jan 13, 2025. The management team acknowledged potential risks and uncertainties that may impact the company’s actual results, as detailed in the company’s most recent quarterly report on Form 10-Q filed with the SEC. RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) 05:45PM Arcus Biosciences, Inc. Gilead will invest $320m in Arcus common stock to Arcus Biosciences is developing a combination therapy of PD-1 and TIGIT inhibitors for esophagogastric cancer, 2023 2:25 AM ET Arcus Biosciences, Inc. Arcus is evaluating zimberelimab in combination with multiple molecules within the Arcus portfolio, including Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December: Evercore 7 th Annual HealthCONx Conference Date: What happened. View real-time RCUS stock price and news, along with industry-best analysis. (NYSE: RCUS) today announced an amendment to their collaboration agreement and Detailed statistics for Arcus Biosciences, Inc. 28, 2023 Roche CEO drags Arcus, iTeos lower after comments on cancer trial Arcus is interested in clinical collaborations that evaluate novel combinations of Arcus molecules with other companies’ medicines or diagnostics to expand our understanding of important pathways and facilitate global Get the Latest News and Ratings for RCUS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. 47%, for an annualized return of -2. Comparatively, Grifols has a beta of 0. What was the 52-week high for Arcus View Arcus Biosciences, Inc RCUS investment & stock information. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected Dec 18. Includes open, high, low, close and volume. CD39 is a key enzyme in the tumor microenvironment that degrades adenosine triphosphate (ATP). It develops immunotherapies for the treatment of cancer. 06M shares representing 32. Try Now>>See Insiders’ Hot Stocks on TipRanks >> Read More on RCUS:Arcus Biosciences Reports Promising Trial ResultsArcus Biosciences price target raised to $46 from $38 at CitiArcus: HIF-2a FOSTER CITY, Calif. 33. co/fees for details. Gilead Sciences and Arcus Biosciences have expanded their oncology partnership agreement and announced a significant equity investment and board-level changes. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody zimberelimab, Find the latest news headlines from Arcus Biosciences, Inc. Arcus Biosciences (RCUS) reported Q3 2024 earnings per share (EPS) of-$1, beating estimates of -$1. Inhibiting CD39 may increase the amount of ATP in the tumor microenvironment, which could lead to enhanced anti-tumor immune response. Arcus Biosciences (NYSE:RCUS) will present first clinical data from the ARC-20 study at the 2024 EORTC-NCI-AACR Symposium. jtbspotpjctzvafivzasulneiyooedgbdnurtdubwwvsexcn